An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons

Molecular Pain

Josephine Lai²  Frank Porreca²  Sam J Shuster¹  Yuan-Yuan Huang²  Shou-Wu Ma²  Dong-Qin Zhang²  Miaw-Chyi Luo² 

[1] Neuromics, Minneapolis, MN 55438, USA;Department of Pharmacology, The University of Arizona Health Sciences Center, Tucson, AZ 85724, USA

关键词: RNA interference;    knockdown;    spinal cord;    sensory neurons;    antinociception;    rat;   

Others  :  1180356
DOI  :  10.1186/1744-8069-1-29

 received in 2005-06-24, accepted in 2005-09-28,  发布年份 2005

【 摘 要 】

We have developed a highly effective method for in vivo gene silencing in the spinal cord and dorsal root ganglia (DRG) by a cationic lipid facilitated delivery of synthetic, small interfering RNA (siRNA). A siRNA to the delta opioid receptor (DOR), or a mismatch RNA, was mixed with the transfection reagent, i-Fect™ (vehicle), and delivered as repeated daily bolus doses (0.5 μg to 4 μg) via implanted intrathecal catheter to the lumbar spinal cord of rats. Twenty-four hours after the last injection, rats were tested for antinociception by the DOR selective agonist, [D-Ala², Glu⁴]deltorphin II (DELT), or the mu opioid receptor (MOR) selective agonist, [D-Ala², N-Me-Phe⁴, Gly-ol⁵]enkephalin (DAMGO). Pretreatment with the siRNA, but not the mismatch RNA or vehicle alone, blocked DELT antinociception dose-dependently. The latter was concomitant with a reduction in the spinal immunoreactivity and receptor density of DOR, and in DOR transcripts in the lumbar DRG and spinal dorsal horn. Neither siRNA nor mismatch RNA pretreatment altered spinal immunoreactivity of MOR or antinociception by spinal DAMGO, and had no effect on the baseline thermal nociceptive threshold. The inhibition of function and expression of DOR by siRNA was reversed by 72 hr after the last RNA injection. The uptake of fluorescence-tagged siRNA was detected in both DRG and spinal cord. The low effective dose of siRNA/i-Fect™ complex reflects an efficient delivery of the siRNA to peripheral and spinal neurons, produced no behavioral signs of toxicity. This delivery method may be optimized for other gene targets.

【 授权许可】

   
2005 Luo et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Hammond SM, Bernstein E, Beach D, Hannon GJ: A genetic link between co-suppression and RNA interference in C. elegans. Nature 2000, 404:293-296.
• [2]Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:906-811.
• [3]Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409:363-366.
• [4]Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
• [5]Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
• [6]McCaffrey AP, Meuse L, Pham T-TT, Conklin DS, Hannon GJ, Kay MA: Gene expression: RNA interference in adult mice. Nature 2002, 418:38-39.
• [7]Song E, Lee S-K, Wang J, Ince N, Quyang N, Min J, Chen J, Shankar P, Lieberman J: RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9:347-351.
• [8]Sorensen DR, Leirdal M, Sioud M: Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003, 327:761-766.
• [9]Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kühnel F, Kubicka S: Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003, 100:7797-7802.
• [10]Kobayashi N, Matsui Y, Kawase A, Hirata K, Miyagishi M, Taira K, Nishikawa M, Takakura Y: Vector-based in vivo RNA interference: dose- and time-dependent suppression of transgene expression. J Pharmaco Exp Ther 2004, 308:688-693.
• [11]Trülzsch B, Wood M: Application of nucleic acid technology in the CNS. J Neurochem 2004, 88:257-265.
• [12]Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM: Highly efficient small interfering RNA delivery to primary mammalian neurons induces microRNA-like effects before mRNA degradation. J Neurosci 2004, 24:10040-10046.
• [13]Makimura H, Mizuno TM, Mastaitis JW, Agami R, Mobbs CV: Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 2002, 3:18-23. BioMed Central Full Text
• [14]Baker-Herman TL, Fuller DD, Bavis RW, Zabka AG, Golder FJ, Doperalski NJ, Johnson RA, Watters JJ, Mitchell GS: BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nat Neurosci 2003, 7:48-55.
• [15]Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJC, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall Jonathan: siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004, 32:e49.
• [16]Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci 2004, 101:17270-17275.
• [17]Lai J, Crook TJ, Payne A, Lynch RM, Porreca F: Antisense targeting of delta opioid receptors in NG108-15 cells: direct correlation between oligodeoxynucleotide uptake and receptor density. J Pharmacol Exp Ther 1997, 281:589-596.
• [18]Bilsky EJ, Bernstein RN, Hruby VJ, Rothman RB, Lai J, Porreca F: Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo. J Pharmacol Exp Ther 1996, 277:491-501.
• [19]Bilsky EJ, Wang T, Lai J, Porreca F: Selective blockade of peripheral delta opioid agonist induced antinociception by intrathecal administration of delta opioid receptor antisense oligodeoxynucleotide. Neurosci Lett 1996, 220:155-158.
• [20]Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong C-M, Zhang E-T, Malan TP Jr, Ossipov MH, Lai J, Porreca F: Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000, 20:7074-7079.
• [21]Wood MJA, Trülzsch B, Abdelgany A, Beeson D: Therapeutic gene silencing in the nervous system. Hum Mol Genet 2003, 12:R279-R284.
• [22]Rossi JJ: A cholesterol connection in RNAi. Nature 2004, 432:155-156.
• [23]Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Röhl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher H-P: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
• [24]More information about this reagent may be obtained on line at [http://www.neuromics.com] webcite
• [25]Hannon GJ: RNA interference. Nature 2002, 418:244-251.
• [26]Novina CD, Sharp PA: The RNAi revolution. Nature 2004, 430:161-164.